

# Ron A A MathÃ't

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1629441/publications.pdf>

Version: 2024-02-01

196  
papers

6,075  
citations

76326

40  
h-index

88630

70  
g-index

196  
all docs

196  
docs citations

196  
times ranked

7275  
citing authors

#	ARTICLE	IF	CITATIONS
1	Loss of Infliximab Into Feces Is Associated With Lack of Response to Therapy in Patients With Severe Ulcerative Colitis. <i>Gastroenterology</i> , 2015, 149, 350-355.e2.	1.3	342
2	Metformin in patients with advanced pancreatic cancer: a double-blind, randomised, placebo-controlled phase 2 trial. <i>Lancet Oncology</i> , The, 2015, 16, 839-847.	10.7	321
3	Cyclosporine Interacts with Mycophenolic Acid by Inhibiting the Multidrug Resistance-Associated Protein 2. <i>American Journal of Transplantation</i> , 2005, 5, 987-994.	4.7	278
4	Impact of Goal-Oriented and Model-Based Clinical Pharmacokinetic Dosing of Aminoglycosides on Clinical Outcome: A Cost-Effectiveness Analysis. <i>Therapeutic Drug Monitoring</i> , 1999, 21, 63-73.	2.0	214
5	High within-patient variability in the clearance of tacrolimus is a risk factor for poor long-term outcome after kidney transplantation. <i>Nephrology Dialysis Transplantation</i> , 2010, 25, 2757-2763.	0.7	210
6	Effect of Intravenous Paracetamol on Postoperative Morphine Requirements in Neonates and Infants Undergoing Major Noncardiac Surgery. <i>JAMA - Journal of the American Medical Association</i> , 2013, 309, 149.	7.4	193
7	Alternative drug formulations of docetaxel: a review. <i>Anti-Cancer Drugs</i> , 2007, 18, 95-103.	1.4	181
8	Explaining Variability in Mycophenolic Acid Exposure to Optimize Mycophenolate Mofetil Dosing. <i>Journal of the American Society of Nephrology: JASN</i> , 2006, 17, 871-880.	6.1	175
9	Pharmacokinetic Features and Presence of Antidrug Antibodies Associate With Response to Infliximab Induction Therapy in Patients With Moderate to Severe Ulcerative Colitis. <i>Clinical Gastroenterology and Hepatology</i> , 2016, 14, 251-258.e2.	4.4	171
10	Population pharmacokinetics of cyclosporine in kidney and heart transplant recipients and the influence of ethnicity and genetic polymorphisms in the and genes. <i>Clinical Pharmacology and Therapeutics</i> , 2004, 76, 545-556.	4.7	153
11	Clinical Pharmacokinetic and Pharmacodynamic Considerations in the Treatment of Ulcerative Colitis. <i>Clinical Pharmacokinetics</i> , 2019, 58, 15-37.	3.5	91
12	Vedolizumab Induces Endoscopic and Histologic Remission in Patients With Crohn's Disease. <i>Gastroenterology</i> , 2019, 157, 997-1006.e6.	1.3	86
13	Population Pharmacokinetics of Mycophenolic Acid in Renal Transplant Recipients. <i>Clinical Pharmacokinetics</i> , 2005, 44, 1083-1096.	3.5	85
14	Population Pharmacokinetics of Mycophenolic Acid. <i>Clinical Pharmacokinetics</i> , 2008, 47, 827-838.	3.5	79
15	Pharmacokinetic role of protein binding of mycophenolic acid and its glucuronide metabolite in renal transplant recipients. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 2009, 36, 541-564.	1.8	73
16	Effect of <i>CYP2C19</i> *2 and *17 mutations on pharmacodynamics and kinetics of proton pump inhibitors in Caucasians. <i>British Journal of Clinical Pharmacology</i> , 2008, 65, 752-760.	2.4	72
17	Interpatient variability in IMPDH activity in MMF-treated renal transplant patients is correlated with IMPDH type II 3757T>C polymorphism. <i>Pharmacogenetics and Genomics</i> , 2009, 19, 626-634.	1.5	71
18	Methotrexate-induced side effects are not due to differences in pharmacokinetics in children with Down syndrome and acute lymphoblastic leukemia. <i>Haematologica</i> , 2010, 95, 1106-1113.	3.5	71

#	ARTICLE	IF	CITATIONS
19	Population Pharmacokinetics of Midazolam and Its Metabolites during Venoarterial Extracorporeal Membrane Oxygenation in Neonates. <i>Clinical Pharmacokinetics</i> , 2010, 49, 407-419.	3.5	69
20	Study protocol of a phase IB/II clinical trial of metformin and chloroquine in patients with IDH1-mutated or IDH2-mutated solid tumours. <i>BMJ Open</i> , 2017, 7, e014961.	1.9	69
21	A simple quantitative method analysing amikacin, gentamicin, and vancomycin levels in human newborn plasma using ion-pair liquid chromatography/tandem mass spectrometry and its applicability to a clinical study. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2014, 951-952, 110-118.	2.3	67
22	Medication use during end-of-life care in a palliative care centre. <i>International Journal of Clinical Pharmacy</i> , 2015, 37, 767-775.	2.1	67
23	Time-dependent clearance of mycophenolic acid in renal transplant recipients. <i>British Journal of Clinical Pharmacology</i> , 2007, 63, 741-752.	2.4	63
24	Medicinal Cannabis Does Not Influence the Clinical Pharmacokinetics of Irinotecan and Docetaxel. <i>Oncologist</i> , 2007, 12, 291-300.	3.7	62
25	Efficacy of dashboard driven dosing of infliximab in inflammatory bowel disease patients; a randomized controlled trial. <i>Scandinavian Journal of Gastroenterology</i> , 2021, 56, 145-154.	1.5	61
26	Nonlinear Relationship between Mycophenolate Mofetil Dose and Mycophenolic Acid Exposure. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2011, 6, 656-663.	4.5	60
27	Therapeutic Drug Monitoring for the Individualization of Docetaxel Dosing: A Randomized Pharmacokinetic Study. <i>Clinical Cancer Research</i> , 2011, 17, 353-362.	7.0	59
28	Pharmacokinetics of Cefotaxime and Desacetylcefotaxime in Infants during Extracorporeal Membrane Oxygenation. <i>Antimicrobial Agents and Chemotherapy</i> , 2010, 54, 1734-1741.	3.2	56
29	Pharmacokinetics and Pharmacodynamics of Midazolam and Metabolites in Nonventilated Infants after Craniofacial Surgery. <i>Anesthesiology</i> , 2006, 105, 1135-1146.	2.5	52
30	Pharmacokinetics and analgesic effects of intravenous propacetamol vs rectal paracetamol in children after major craniofacial surgery. <i>Paediatric Anaesthesia</i> , 2008, 18, 582-592.	1.1	52
31	Microanalysis of $^{14}C$ -Lactam Antibiotics and Vancomycin in Plasma for Pharmacokinetic Studies in Neonates. <i>Antimicrobial Agents and Chemotherapy</i> , 2009, 53, 75-80.	3.2	52
32	Sildenafil exposure in neonates with pulmonary hypertension after administration via a nasogastric tube. <i>Archives of Disease in Childhood: Fetal and Neonatal Edition</i> , 2010, 95, F109-F114.	2.8	52
33	Improved Assay for the Nonradioactive Determination of Inosine 5'-Monophosphate Dehydrogenase Activity in Peripheral Blood Mononuclear Cells. <i>Therapeutic Drug Monitoring</i> , 2009, 31, 351-359.	2.0	51
34	Pharmacokinetics of Aztreonam in Healthy Subjects and Patients with Cystic Fibrosis and Evaluation of Dose-Exposure Relationships Using Monte Carlo Simulation. <i>Antimicrobial Agents and Chemotherapy</i> , 2007, 51, 3049-3055.	3.2	50
35	Performing and interpreting individual pharmacokinetic profiles in patients with Hemophilia A or B: Rationale and general considerations. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2018, 2, 535-548.	2.3	50
36	Bayesian Pharmacokinetically Guided Dosing of Paclitaxel in Patients with Non-Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2004, 10, 2237-2244.	7.0	47

#	ARTICLE	IF	CITATIONS
37	Caspofungin: antifungal activity in vitro, pharmacokinetics, and effects on fungal load and animal survival in neutropenic rats with invasive pulmonary aspergillosis. <i>Journal of Antimicrobial Chemotherapy</i> , 2006, 57, 732-740.	3.0	46
38	Phase II Feasibility and Biomarker Study of Neoadjuvant Trastuzumab and Pertuzumab With Chemoradiotherapy for Resectable Human Epidermal Growth Factor Receptor 2-Positive Esophageal Adenocarcinoma: TRAP Study. <i>Journal of Clinical Oncology</i> , 2020, 38, 462-471.	1.6	44
39	Pharmacokinetics and pharmacodynamics of medication in asphyxiated newborns during controlled hypothermia. The PharmaCool multicenter study. <i>BMC Pediatrics</i> , 2012, 12, 45.	1.7	43
40	Population pharmacokinetics of paracetamol across the human age-range from (pre)term neonates, infants, children to adults. <i>Journal of Clinical Pharmacology</i> , 2014, 54, 619-629.	2.0	42
41	Combination Therapy of Advanced Invasive Pulmonary Aspergillosis in Transiently Neutropenic Rats Using Human Pharmacokinetic Equivalent Doses of Voriconazole and Anidulafungin. <i>Antimicrobial Agents and Chemotherapy</i> , 2009, 53, 2005-2013.	3.2	41
42	Mycophenolic Acid in Diabetic Renal Transplant Recipients. <i>Therapeutic Drug Monitoring</i> , 2004, 26, 620-625.	2.0	40
43	External Evaluation of Population Pharmacokinetic Models of Vancomycin in Large Cohorts of Intensive Care Unit Patients. <i>Antimicrobial Agents and Chemotherapy</i> , 2019, 63, .	3.2	40
44	Efficacy and safety of FOLFIRINOX as salvage treatment in advanced biliary tract cancer: an open-label, single arm, phase 2 trial. <i>British Journal of Cancer</i> , 2020, 122, 634-639.	6.4	40
45	Pharmacokinetics of Mycophenolate Mofetil in Hematopoietic Stem Cell Transplant Recipients. <i>Therapeutic Drug Monitoring</i> , 2007, 29, 353-360.	2.0	39
46	A population pharmacokinetic model for perioperative dosing of factor VIII in hemophilia A patients. <i>Haematologica</i> , 2016, 101, 1159-1169.	3.5	39
47	Influence of high-dose ketoconazole on the pharmacokinetics of docetaxel. <i>Cancer Biology and Therapy</i> , 2006, 5, 833-839.	3.4	38
48	Intra-patient variability in tacrolimus trough concentrations and renal function decline in pediatric renal transplant recipients. <i>Pediatric Transplantation</i> , 2012, 16, 613-618.	1.0	38
49	Inadequate vancomycin therapy in term and preterm neonates: a retrospective analysis of trough serum concentrations in relation to minimal inhibitory concentrations. <i>BMC Pediatrics</i> , 2014, 14, 193.	1.7	36
50	Altered gentamicin pharmacokinetics in term neonates undergoing controlled hypothermia. <i>British Journal of Clinical Pharmacology</i> , 2016, 81, 1067-1077.	2.4	36
51	Pharmacokinetic Modelling of the Plasma Protein Binding of Mycophenolic Acid in Renal Transplant Recipients. <i>Clinical Pharmacokinetics</i> , 2009, 48, 463-476.	3.5	35
52	Differences in Clearance of Mycophenolic Acid Among Renal Transplant Recipients, Hematopoietic Stem Cell Transplant Recipients, and Patients With Autoimmune Disease. <i>Therapeutic Drug Monitoring</i> , 2010, 32, 606-614.	2.0	34
53	Quantification of levetiracetam in plasma of neonates by ultra performance liquid chromatography-tandem mass spectrometry. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2010, 878, 675-681.	2.3	33
54	Predicting the Usefulness of Therapeutic Drug Monitoring of Mycophenolic Acid. <i>Therapeutic Drug Monitoring</i> , 2005, 27, 163-167.	2.0	32

#	ARTICLE	IF	CITATIONS
55	Therapeutic drug monitoring of mycophenolic acid: does it improve patient outcome?. Expert Opinion on Drug Metabolism and Toxicology, 2007, 3, 251-261.	3.3	32
56	Limited Sampling Strategies for Therapeutic Drug Monitoring of Mycophenolate Mofetil Therapy in Patients With Autoimmune Disease. Therapeutic Drug Monitoring, 2009, 31, 382-390.	2.0	31
57	Estimation of the glomerular filtration rate in children: which algorithm should be used?. Pediatric Nephrology, 2005, 20, 1769-1775.	1.7	30
58	Determinants of gentamicin concentrations in critically ill patients: a population pharmacokinetic analysis. International Journal of Antimicrobial Agents, 2017, 49, 204-211.	2.5	30
59	Within-Patient Variability of Mycophenolic Acid Exposure. Therapeutic Drug Monitoring, 2006, 28, 31-34.	2.0	28
60	Limited Sampling Strategies Drawn Within 3 Hours Postdose Poorly Predict Mycophenolic Acid Area-Under-the-Curve After Enteric-Coated Mycophenolate Sodium. Therapeutic Drug Monitoring, 2009, 31, 585-591.	2.0	27
61	The Effect of Weight and CYP3A5 Genotype on the Population Pharmacokinetics of Tacrolimus in Stable Paediatric Renal Transplant Recipients. Clinical Pharmacokinetics, 2016, 55, 1129-1143.	3.5	27
62	Short-Term Fasting Alters Cytochrome P450âMediated Drug Metabolism in Humans. Drug Metabolism and Disposition, 2015, 43, 819-828.	3.3	26
63	Pharmacodynamics and Pharmacokinetics of Morphine After Cardiac Surgery in Children With and Without Down Syndrome. Pediatric Critical Care Medicine, 2016, 17, 930-938.	0.5	26
64	Pharmacokinetics and pharmacodynamic target attainment of ceftriaxone in adult severely ill sub-Saharan African patients: a population pharmacokinetic modelling study. Journal of Antimicrobial Chemotherapy, 2018, 73, 1620-1629.	3.0	26
65	Explaining Interpatient Variability in Adalimumab Pharmacokinetics in Patients With Crohn's Disease. Therapeutic Drug Monitoring, 2018, 40, 202-211.	2.0	26
66	Dried blood samples can support monitoring of infliximab concentrations in patients with inflammatory bowel disease: A clinical validation. British Journal of Clinical Pharmacology, 2019, 85, 1544-1551.	2.4	26
67	Optimal Sampling Strategies to Assess Inulin Clearance in Children by the Inulin Single-Injection Method. Clinical Chemistry, 2003, 49, 1170-1179.	3.2	25
68	Population pharmacokinetics of intravenous clonidine for sedation during paediatric extracorporeal membrane oxygenation and continuous venovenous hemofiltration. British Journal of Clinical Pharmacology, 2017, 83, 1227-1239.	2.4	24
69	Population pharmacokinetics of subcutaneous infliximab CTâP13 in Crohnâs disease and ulcerative colitis. Alimentary Pharmacology and Therapeutics, 2021, 54, 1309-1319.	3.7	24
70	Inosine Monophosphate Dehydrogenase Messenger RNA Expression Is Correlated to Clinical Outcomes in Mycophenolate Mofetil-Treated Kidney Transplant Patients, Whereas Inosine Monophosphate Dehydrogenase Activity Is Not. Therapeutic Drug Monitoring, 2009, 31, 549-556.	2.0	23
71	Pharmacokinetics of Morphine, Morphine-3-Glucuronide and Morphine-6-Glucuronide in Terminally Ill Adult Patients. Clinical Pharmacokinetics, 2016, 55, 697-709.	3.5	23
72	Hypoalbuminaemia and decreased midazolam clearance in terminally ill adult patients, an inflammatory effect?. British Journal of Clinical Pharmacology, 2017, 83, 1701-1712.	2.4	23

#	ARTICLE	IF	CITATIONS
73	Irinotecan chemotherapy during valproic acid treatment: Pharmacokinetic interaction and hepatotoxicity. <i>Cancer Biology and Therapy</i> , 2007, 6, 1364-1370.	3.4	22
74	Acute liver failure after recommended doses of acetaminophen in patients with myopathies. <i>Critical Care Medicine</i> , 2011, 39, 678-682.	0.9	22
75	The "OPTI-CLOT" trial. <i>Thrombosis and Haemostasis</i> , 2015, 114, 639-644.	3.4	22
76	CNS penetration of ART in HIV-infected children. <i>Journal of Antimicrobial Chemotherapy</i> , 2018, 73, 484-489.	3.0	21
77	Quantification of midazolam, morphine and metabolites in plasma using well solid-phase extraction and ultra-performance liquid chromatography-tandem mass spectrometry. <i>Biomedical Chromatography</i> , 2010, 24, 969-976.	1.7	20
78	Therapeutic Drug Monitoring of Gentamicin Peak Concentrations in Critically Ill Patients. <i>Therapeutic Drug Monitoring</i> , 2017, 39, 522-530.	2.0	20
79	The effects of fasting on drug metabolism. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2020, 16, 79-85.	3.3	20
80	Individualisation of mycophenolate mofetil dose in renal transplant recipients. <i>Expert Opinion on Pharmacotherapy</i> , 2006, 7, 361-376.	1.8	19
81	Ultrafast selective quantification of methotrexate in human plasma by high-throughput MALDI-isotope dilution mass spectrometry. <i>Bioanalysis</i> , 2011, 3, 1369-1378.	1.5	18
82	Effect of Short-Term Fasting on Systemic Cytochrome P450-Mediated Drug Metabolism in Healthy Subjects: A Randomized, Controlled, Crossover Study Using a Cocktail Approach. <i>Clinical Pharmacokinetics</i> , 2017, 56, 1231-1244.	3.5	18
83	Modelling of the relationship between infliximab exposure, faecal calprotectin and endoscopic remission in patients with Crohn's disease. <i>British Journal of Clinical Pharmacology</i> , 2021, 87, 106-118.	2.4	18
84	Simultaneous assay of sildenafil and desmethylsildenafil in neonatal plasma by ultra-performance liquid chromatography-tandem mass spectrometry. <i>Biomedical Chromatography</i> , 2010, 24, 180-185.	1.7	17
85	Population Pharmacokinetics and Dosing Considerations for Gentamicin in Newborns with Suspected or Proven Sepsis Caused by Gram-Negative Bacteria. <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .	3.2	16
86	Population pharmacodynamic modelling of midazolam induced sedation in terminally ill adult patients. <i>British Journal of Clinical Pharmacology</i> , 2018, 84, 320-330.	2.4	16
87	Pharmacokinetics of golimumab in moderate to severe ulcerative colitis: the GO-KINETIC study. <i>Scandinavian Journal of Gastroenterology</i> , 2019, 54, 700-706.	1.5	16
88	Prevention of relapses with levamisole as adjuvant therapy in children with a first episode of idiopathic nephrotic syndrome: study protocol for a double blind, randomised placebo-controlled trial (the LEARNs study). <i>BMJ Open</i> , 2019, 9, e027011.	1.9	16
89	Pharmacodynamic monitoring of factor VIII replacement therapy in hemophilia A: Combining thrombin and plasmin generation. <i>Journal of Thrombosis and Haemostasis</i> , 2020, 18, 3222-3231.	3.8	16
90	Clinical Pharmacokinetics of Gentamicin in Various Patient Populations and Consequences for Optimal Dosing for Gram-Negative Infections: An Updated Review. <i>Clinical Pharmacokinetics</i> , 2022, 61, 1075-1094.	3.5	16

#	ARTICLE	IF	CITATIONS
91	Caspofungin Prolongs Survival of Transiently Neutropenic Rats with Advanced-Stage Invasive Pulmonary Aspergillosis. <i>Antimicrobial Agents and Chemotherapy</i> , 2008, 52, 1345-1350.	3.2	15
92	Effect of hypothermia and extracorporeal life support on drug disposition in neonates. <i>Seminars in Fetal and Neonatal Medicine</i> , 2013, 18, 23-27.	2.3	15
93	A phase Ib study of everolimus combined with metformin for patients with advanced cancer. <i>Investigational New Drugs</i> , 2018, 36, 53-61.	2.6	15
94	Combining Brain Microdialysis and Translational Pharmacokinetic Modeling to Predict Drug Concentrations in Pediatric Severe Traumatic Brain Injury: The Next Step Toward Evidence-Based Pharmacotherapy?. <i>Journal of Neurotrauma</i> , 2019, 36, 111-117.	3.4	15
95	Population pharmacokinetics of intravenous Erwinia asparaginase in pediatric acute lymphoblastic leukemia patients. <i>Haematologica</i> , 2017, 102, 552-561.	3.5	14
96	Influence of ketoconazole on the fecal and urinary disposition of docetaxel. <i>Cancer Chemotherapy and Pharmacology</i> , 2007, 60, 569-579.	2.3	13
97	Pharmacokinetics of dabigatran etexilate and rivaroxaban in patients with short bowel syndrome requiring parenteral nutrition: The PDER PAN study. <i>Thrombosis Research</i> , 2017, 160, 76-82.	1.7	13
98	Monitoring of Adalimumab Concentrations at Home in Patients with Inflammatory Bowel Disease Using Dried Blood Samples. <i>Therapeutic Drug Monitoring</i> , 2020, 42, 289-294.	2.0	13
99	A Phase Ib Clinical Trial of Metformin and Chloroquine in Patients with IDH1-Mutated Solid Tumors. <i>Cancers</i> , 2021, 13, 2474.	3.7	13
100	Population Pharmacokinetics and Pharmacodynamics of Nelfinavir and Its Active Metabolite M8 in HIV-1-Infected Children. <i>Pediatric Infectious Disease Journal</i> , 2006, 25, 538-543.	2.0	12
101	A short-term high fat diet increases exposure to midazolam and omeprazole in healthy subjects. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2016, 12, 715-720.	3.3	12
102	Pharmacokinetics of Sâ€œketamine during prolonged sedation at the pediatric intensive care unit. <i>Paediatric Anaesthesia</i> , 2017, 27, 1098-1107.	1.1	12
103	An effective modestly intensive reâ€œinduction regimen with bortezomib in relapsed or refractory paediatric acute lymphoblastic leukaemia. <i>British Journal of Haematology</i> , 2018, 181, 523-527.	2.5	12
104	Target site antibiotic concentrations in orthopedic/trauma extremity surgery: is prophylactic cefazolin adequately dosed? A systematic review and meta-analysis. <i>Monthly Notices of the Royal Astronomical Society: Letters</i> , 2019, 90, 97-104.	3.3	12
105	Prediction of Drug Exposure in Critically Ill Encephalopathic Neonates Treated With Therapeutic Hypothermia Based on a Pooled Population Pharmacokinetic Analysis of Seven Drugs and Five Metabolites. <i>Clinical Pharmacology and Therapeutics</i> , 2020, 108, 1098-1106.	4.7	12
106	Enhanced Paracetamol Clearance with Molecular Adsorbents Recirculating System (MARSÂ®) in Severe Autointoxication. <i>Blood Purification</i> , 2010, 30, 118-119.	1.8	11
107	Sorafenib for Patients with Hepatocellular Carcinoma and Child-Pugh B Liver Cirrhosis: Lessons Learned from a Terminated Study. <i>Oncologist</i> , 2020, 25, e1274-e1279.	3.7	11
108	Development and validation of an LC-MS/MS method for simultaneous quantification of co-administered trastuzumab and pertuzumab. <i>MAbs</i> , 2020, 12, 1795-1799.	5.2	11

#	ARTICLE	IF	CITATIONS
109	The value of sorafenib trough levels in patients with advanced hepatocellular carcinoma â€“ a substudy of the SORAMIC trial. <i>Acta OncolÄ³gica</i> , 2020, 59, 1028-1035.	1.8	11
110	Individualized dosing guidelines for PEGasparaginase and factors influencing the clearance: a population pharmacokinetic model. <i>Haematologica</i> , 2021, 106, 1254-1261.	3.5	11
111	Quantitative Method for Simultaneous Analysis of a 5-Probe Cocktail for Cytochrome P450 Enzymes. <i>Therapeutic Drug Monitoring</i> , 2016, 38, 761-768.	2.0	10
112	Strategies for Individualized Dosing of Clotting Factor Concentrates and Desmopressin in Hemophilia A and B. <i>Therapeutic Drug Monitoring</i> , 2019, 41, 192-212.	2.0	10
113	Pharmacokinetic/pharmacodynamic target attainment of ciprofloxacin in adult patients on general wards with adequate and impaired renal function. <i>International Journal of Antimicrobial Agents</i> , 2020, 56, 106166.	2.5	10
114	Does dose reduction of renally cleared antibiotics in patients with impaired renal function lead to adequate drug exposure? A systematic review. <i>Clinical Microbiology and Infection</i> , 2021, 27, 352-363.	6.0	10
115	Differential effects of a 40-hour fast and bile acid supplementation on human GLP-1 and FGF19 responses. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2019, 317, E494-E502.	3.5	9
116	Optimising the dose of clonidine to achieve sedation in intensive care unit patients with population pharmacokinetics. <i>British Journal of Clinical Pharmacology</i> , 2020, 86, 1620-1631.	2.4	9
117	Population Pharmacokinetics and Probability of Target Attainment of Different Dosing Regimens of Cefazidime in Critically Ill Patients with a Proven or Suspected <i>Pseudomonas aeruginosa</i> Infection. <i>Antibiotics</i> , 2021, 10, 612.	3.7	9
118	Current Ceftriaxone Dose Recommendations are Adequate for Most Critically Ill Children: Results of a Population Pharmacokinetic Modeling and Simulation Study. <i>Clinical Pharmacokinetics</i> , 2021, 60, 1361-1372.	3.5	9
119	Pharmacokinetic-Pharmacodynamic Model of Vedolizumab for Targeting Endoscopic Remission in Patients With Crohn Disease: Posthoc Analysis of the LOVE-CD Study. <i>Inflammatory Bowel Diseases</i> , 2022, 28, 689-699.	1.9	9
120	Perioperative pharmacokinetic-guided factor VIII concentrate dosing in haemophilia (OPTI-CLOT trial): an open-label, multicentre, randomised, controlled trial. <i>Lancet Haematology</i> , the, 2021, 8, e492-e502.	4.6	9
121	Efficacy and safety of FOLFIRINOX in advanced biliary tract cancer after failure of gemcitabine plus cisplatin: A phase II trial.. <i>Journal of Clinical Oncology</i> , 2019, 37, 4086-4086.	1.6	9
122	Saliva as a sampling matrix for therapeutic drug monitoring of gentamicin in neonates: A prospective population pharmacokinetic and simulation study. <i>British Journal of Clinical Pharmacology</i> , 2022, 88, 1845-1855.	2.4	9
123	Nonlinear Mixed Effects Modeling of the Diurnal Blood Pressure Profile in a Multiracial Population. <i>American Journal of Hypertension</i> , 2013, 26, 1103-1113.	2.0	8
124	Pharmacokinetic-guided dosing of factor VIII concentrate in a patient with haemophilia during renal transplantation. <i>BMJ Case Reports</i> , 2016, 2016, bcr2016217069.	0.5	8
125	Prevalence and Implications of Abnormal Laboratory Results in Patients in the Terminal Phase of Life. <i>Journal of Palliative Medicine</i> , 2016, 19, 822-829.	1.1	8
126	Evaluation of a System-Specific Function To Describe the Pharmacokinetics of Benzylpenicillin in Term Neonates Undergoing Moderate Hypothermia. <i>Antimicrobial Agents and Chemotherapy</i> , 2018, 62, .	3.2	8



#	ARTICLE	IF	CITATIONS
127	Short-Term Fasting Alters Pharmacokinetics of Cytochrome P450 Probe Drugs: Does Protein Binding Play a Role?. <i>European Journal of Drug Metabolism and Pharmacokinetics</i> , 2018, 43, 251-257.	1.6	8
128	Pharmacokinetic Modelling to Predict FVIII:C Response to Desmopressin and Its Reproducibility in Nonsevere Haemophilia A Patients. <i>Thrombosis and Haemostasis</i> , 2018, 47, 621-629.	3.4	8
129	Tumor necrosis factor-mediated disposition of infliximab in ulcerative colitis patients. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 2019, 46, 543-551.	1.8	8
130	Population Pharmacokinetics of Ganciclovir in Critically Ill Patients. <i>Therapeutic Drug Monitoring</i> , 2020, 42, 295-301.	2.0	8
131	A Novel, Enriched Population Pharmacokinetic Model for Recombinant Factor VIII-Fc Fusion Protein Concentrate in Hemophilia A Patients. <i>Thrombosis and Haemostasis</i> , 2020, 120, 747-757.	3.4	8
132	Optimizing Predictive Performance of Bayesian Forecasting for Vancomycin Concentration in Intensive Care Patients. <i>Pharmaceutical Research</i> , 2020, 37, 171.	3.5	8
133	Deep compartment models: A deep learning approach for the reliable prediction of time-series data in pharmacokinetic modeling. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2022, 11, 934-945.	2.5	8
134	Application of SHAP values for inferring the optimal functional form of covariates in pharmacokinetic modeling. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2022, 11, 1100-1110.	2.5	8
135	Golimumab for moderate to severe ulcerative colitis. <i>Expert Review of Gastroenterology and Hepatology</i> , 2017, 11, 401-406.	3.0	7
136	Nutritional Status Differentially Alters Cytochrome P450 3A4 (CYP3A4) and Uridine 5- <sup>2</sup> -Diphospho-Glucuronosyltransferase (UGT) Mediated Drug Metabolism: Effect of Short-Term Fasting and High Fat Diet on Midazolam Metabolism. <i>European Journal of Drug Metabolism and Pharmacokinetics</i> , 2018, 43, 751-767.	1.6	7
137	Desmopressin treatment combined with clotting factor VIII concentrates in patients with non-severe haemophilia A: protocol for a multicentre single-armed trial, the DAVID study. <i>BMJ Open</i> , 2019, 9, e022719.	1.9	7
138	Population Pharmacokinetics with Monte Carlo Simulations of Gentamicin in a Population of Severely Ill Adult Patients from Sub-Saharan Africa. <i>Antimicrobial Agents and Chemotherapy</i> , 2019, 63, .	3.2	7
139	Rapid stromal remodeling by short-term VEGFR2 inhibition increases chemotherapy delivery in esophagogastric adenocarcinoma. <i>Molecular Oncology</i> , 2020, 14, 704-720.	4.6	7
140	Pharmacokinetics and population pharmacokinetics in pediatric oncology. <i>Pediatric Blood and Cancer</i> , 2020, 67, e28132.	1.5	7
141	Peginterferon and Dose-Titrated Ribavirin for Hepatitis C-Associated Nephrotic Membranoproliferative Glomerulonephritis Type 1. <i>Digestive Diseases and Sciences</i> , 2005, 50, 1804-1806.	2.3	6
142	Pharmacokinetic-Pharmacodynamic Modeling of the Antihypertensive Effect of Eprosartan in Black and White Hypertensive Patients. <i>Clinical Pharmacokinetics</i> , 2013, 52, 793-803.	3.5	6
143	Clinical Evaluation of Vancomycin Dosage in Pediatric Oncology Patients. <i>Pediatric Infectious Disease Journal</i> , 2014, 33, 731-733.	2.0	6
144	One piece of the puzzle: Population pharmacokinetics of FVIII during perioperative Haemate PÄ®/Humate PÄ® treatment in von Willebrand disease patients. <i>Journal of Thrombosis and Haemostasis</i> , 2020, 18, 295-305.	3.8	6

#	ARTICLE	IF	CITATIONS
145	Dosing of factor VIII concentrate by ideal body weight is more accurate in overweight and obese haemophilia A patients. <i>British Journal of Clinical Pharmacology</i> , 2021, 87, 2602-2613.	2.4	6
146	Combining factor VIII levels and thrombin/plasmin generation: A population pharmacokineticâ€pharmacodynamic model for patients with haemophilia A. <i>British Journal of Clinical Pharmacology</i> , 2022, 88, 2757-2768.	2.4	6
147	SYMPHONY consortium: Orchestrating personalized treatment for patients with bleeding disorders. <i>Journal of Thrombosis and Haemostasis</i> , 2022, 20, 2001-2011.	3.8	6
148	Quantitative Method for Simultaneous Analysis of Acetaminophen and 6 Metabolites. <i>Therapeutic Drug Monitoring</i> , 2017, 39, 172-179.	2.0	5
149	Systemic effects of angiogenesis inhibition alter pharmacokinetics and intratumoral delivery of nab-paclitaxel. <i>Drug Delivery</i> , 2017, 24, 1801-1810.	5.7	5
150	von Willebrand Factor and Factor VIII Clearance in Perioperative Hemophilia A Patients. <i>Thrombosis and Haemostasis</i> , 2020, 120, 1056-1065.	3.4	5
151	Population pharmacokinetics of the von Willebrand factorâ€factor VIII interaction in patients with von Willebrand disease. <i>Blood Advances</i> , 2021, 5, 1513-1522.	5.2	5
152	Comparison of the Pharmacokinetic Properties of Extended Half-Life and Recombinant Factor VIII Concentrates by In Silico Simulations. <i>Thrombosis and Haemostasis</i> , 2021, 121, 731-740.	3.4	5
153	A phase II randomized, placebo controlled study to evaluate the efficacy of the combination of gemcitabine, erlotinib, and metformin in patients with locally advanced or metastatic pancreatic cancer.. <i>Journal of Clinical Oncology</i> , 2014, 32, 4021-4021.	1.6	5
154	Paracetamol clinical dosing routine leads to paracetamol underexposure in an adult severely ill sub-Saharan African hospital population: a drug concentration measurement study. <i>BMC Research Notes</i> , 2017, 10, 671.	1.4	4
155	Positioning extended half-life concentrates for future use: a practical proposal. <i>Haemophilia</i> , 2018, 24, e369-e372.	2.1	4
156	Current dosing practices for perioperative factor VIII concentrate treatment in mild haemophilia A patients result in FVIII levels above target. <i>Haemophilia</i> , 2019, 25, 960-968.	2.1	4
157	Pharmacokinetics of prednisolone in children: an open-label, randomised, two-treatment cross-over trial investigating the bioequivalence of different prednisolone formulations in children with airway disease. <i>BMJ Paediatrics Open</i> , 2019, 3, e000520.	1.4	4
158	Why we should sample sparsely and aim for a higher target: Lessons from model-based therapeutic drug monitoring of vancomycin in intensive care patients. <i>British Journal of Clinical Pharmacology</i> , 2021, 87, 1234-1242.	2.4	4
159	Validation of a perioperative population factor VIII pharmacokinetic model with a large cohort of pediatric hemophilia a patients. <i>British Journal of Clinical Pharmacology</i> , 2021, 87, 4408-4420.	2.4	4
160	Sample Collection, Biobanking, and Analysis. <i>Handbook of Experimental Pharmacology</i> , 2011, 205, 203-217.	1.8	4
161	Feasibility study of trastuzumab (T) and pertuzumab (P) added to neoadjuvant chemoradiotherapy (nCRT) in resectable HER2+ esophageal adenocarcinoma (EAC) patients (pts): The TRAP study.. <i>Journal of Clinical Oncology</i> , 2018, 36, 4057-4057.	1.6	4
162	Serum drug levels and anti-drug antibodies in the context of dose tapering by interval prolongation of adalimumab, etanercept and ustekinumab in psoriasis patients: results of the CONDOR trial. <i>Journal of Dermatological Treatment</i> , 2022, 33, 2680-2684.	2.2	4

#	ARTICLE	IF	CITATIONS
163	Pharmacokinetics and Pharmacodynamic Target Attainment of Benzylpenicillin in an Adult Severely Ill Sub-Saharan African Patient Population. <i>Clinical Infectious Diseases</i> , 2018, 66, 1261-1269.	5.8	3
164	832 â Dashboard Driven Dosing of Infliximab is Superior to Conventional Treatment in Inflammatory Bowel Disease: the Precision Randomized Controlled Trial. <i>Gastroenterology</i> , 2019, 156, S-180-S-181.	1.3	3
165	Population Pharmacokinetic Modeling of von Willebrand Factor Activity in von Willebrand Disease Patients after Desmopressin Administration. <i>Thrombosis and Haemostasis</i> , 2020, 120, 1407-1416.	3.4	3
166	Population Pharmacokinetics of Clotting Factor Concentrates and Desmopressin in Hemophilia. <i>Clinical Pharmacokinetics</i> , 2021, 60, 1-16.	3.5	3
167	In silico comparison of pharmacokinetic properties of three extended half-life factor IX concentrates. <i>European Journal of Clinical Pharmacology</i> , 2021, 77, 1193-1200.	1.9	3
168	Evaluation of the pharmacokinetics of prednisolone in paediatric patients with acute lymphoblastic leukaemia treated according to Dutch Childhood Oncology Group protocols and its relation to treatment response. <i>British Journal of Haematology</i> , 2021, 194, 423-432.	2.5	3
169	Pharmacokinetics of perioperative FVIII in adult patients with haemophilia A: An external validation and development of an alternative population pharmacokinetic model. <i>Haemophilia</i> , 2021, 27, 974-983.	2.1	3
170	Population pharmacokinetic modeling of factor concentrates in hemophilia: an overview and evaluation of best practice. <i>Blood Advances</i> , 2021, 5, 4314-4325.	5.2	3
171	A phase Ib/II study of regorafenib and paclitaxel in patients with beyond first-line advanced esophagogastric carcinoma (REPEAT). <i>Therapeutic Advances in Medical Oncology</i> , 2022, 14, 175883592211091.	3.2	3
172	Pharmacokinetic-guided dosing of factor VIII concentrate in a morbidly obese severe haemophilia A patient undergoing orthopaedic surgery. <i>BMJ Case Reports</i> , 2019, 12, bcr-2018-226812.	0.5	2
173	A Phase II Study Demonstrates No Feasibility of Adjuvant Treatment with Six Cycles of S-1 and Oxaliplatin in Resectable Esophageal Adenocarcinoma, with ERCC1 as Biomarker for Response to SOX. <i>Cancers</i> , 2021, 13, 839.	3.7	2
174	Perioperative FVIII Concentrate Treatment in Mild Hemophilia a Patients Shows a High Rate of Overdosing - David/Opti-Clot Studies. <i>Blood</i> , 2015, 126, 3510-3510.	1.4	2
175	A novel 6-mercaptopurine oral liquid formulation for pediatric acute lymphoblastic leukemia patients â results of a randomized clinical trial. <i>International Journal of Clinical Pharmacology and Therapeutics</i> , 2014, 52, 653-662.	0.6	2
176	Population Pharmacokinetics of Erwinia Asparaginase in Pediatric ALL Patients. <i>Blood</i> , 2015, 126, 1281-1281.	1.4	2
177	Development and Validation of a Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS) Assay for the Determination of Total and Unbound Ciprofloxacin Concentrations in Human Plasma. <i>Therapeutic Drug Monitoring</i> , 2022, Publish Ahead of Print, .	2.0	2
178	Is pharmacokinetic-guided dosing of desmopressin and von Willebrand factor-containing concentrates in individuals with von Willebrand disease or low von Willebrand factor reliable and feasible? A protocol for a multicentre, non-randomised, open label cohort trial, the OPTI-CLOT: to WiN study. <i>BMJ Open</i> , 2022, 12, e049493.	1.9	2
179	Does difference between label and actual potency of factor VIII concentrate affect pharmacokineticâguided dosing of replacement therapy in haemophilia A?. <i>Haemophilia</i> , 2022, , .	2.1	2
180	Time-Dependent Clearance Decrements of Fluvoxamine in Depressed Inpatients. <i>Journal of Clinical Psychopharmacology</i> , 2007, 27, 231-233.	1.4	1

#	ARTICLE	IF	CITATIONS
181	Wound infection following implant removal of foot, ankle, lower leg or patella; a protocol for a multicenter randomized controlled trial investigating the (cost-)effectiveness of 2Äg of prophylactic cefazolin compared to placebo (WIFI-2 trial). BMC Surgery, 2021, 21, 69.	1.3	1
182	Development and Validation of a Highly Sensitive Liquid Chromatography-Tandem Mass Spectrometry Technique to Determine Levamisole in Plasma and Saliva. Therapeutic Drug Monitoring, 2021, 43, 279-285.	2.0	1
183	Population pharmacokinetics of infliximab in children with juvenile idiopathic arthritis. Therapeutic Drug Monitoring, 2021, Publish Ahead of Print, .	2.0	1
184	A Novel Quantitative Method for Analyzing Desmopressin in Human Plasma Using Liquid Chromatography-Tandem Mass Spectrometry. Therapeutic Drug Monitoring, 2020, 42, 880-885.	2.0	1
185	Sedation With Midazolam After Cardiac Surgery in Children With and Without Down Syndrome: A Pharmacokinetic-Pharmacodynamic Study. Pediatric Critical Care Medicine, 2021, 22, e259-e269.	0.5	1
186	Phase II Study on Bortezomib (BTZ) in Multiple Relapsed or Refractory Pediatric Acute Lymphoblastic Leukemia (rALL): High Response Rate with a Modestly Intensive Regimen Including BTZ, Not Related to Pharmacokinetics. Blood, 2015, 126, 2501-2501.	1.4	1
187	Design of a Prospective Study on Pharmacokinetic-Guided Dosing of Prophylactic Factor Replacement in Hemophilia A and B (OPTI-CLOT TARGET Study). TH Open, 2022, 06, e60-e69.	1.4	1
188	Population pharmacokinetics of intravenous cefotaxime indicates that higher doses are required for critically ill children. Journal of Antimicrobial Chemotherapy, 2022, 77, 1725-1732.	3.0	1
189	Quantification of the relationship between desmopressin concentration and Von Willebrand factor in Von Willebrand disease type 1: A pharmacodynamic study. Haemophilia, 2022, 28, 814-821.	2.1	1
190	The association between desmopressin exposure, FVIII response and side effects. Haemophilia, 2021, 27, e506-e509.	2.1	0
191	Transcapillary escape rate of 125I-albumin in relation to timing of blood sampling: the need for standardization. EJNMMI Radiopharmacy and Chemistry, 2021, 6, 9.	3.9	0
192	Targeting Clotting Factor VIII Plasma Values in the Perioperative Setting in Hemophilia a: Tackling a Moving Target (OPTI-CLOT Studies). Blood, 2014, 124, 5031-5031.	1.4	0
193	Pharmacokinetics of midazolam and its metabolites in terminally ill adult patients.. Journal of Clinical Oncology, 2016, 34, e21506-e21506.	1.6	0
194	Phase I study of everolimus combined with metformin for patients with advanced cancer.. Journal of Clinical Oncology, 2016, 34, e14088-e14088.	1.6	0
195	Survival analysis of a phase IB/II study of everolimus and metformin for patients with advanced cancer.. Journal of Clinical Oncology, 2017, 35, e14020-e14020.	1.6	0
196	Editorial: subcutaneous CTÄP13 in CrohnÄ™s disease and ulcerative colitisÄ™small change, big consequences. Authors' reply. Alimentary Pharmacology and Therapeutics, 2022, 55, 253-254.	3.7	0